



L10 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1996:338506 CAPLUS  
 DOCUMENT NUMBER: 125:114539  
 TITLE: Cyclocondensation of activated (ortho-chloroaryl)acetylenes with hydrazine: a novel route to substituted indazoles  
 AUTHOR(S): Vasilevsky, Sergey F.; Prikhod'ko, Tat'yana A.  
 CORPORATE SOURCE: Inst. Chem. Kinetics and Combustion, Siberian Branch Russian Acad. Sci., Novosibirsk, 630090, Russia  
 SOURCE: Mendelev Comm. (1996), (3), 98-99  
 CODEN: MENCEX; ISSN: 0959-9436  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI




I




II

AB The reaction of (ortho-chloroaryl)acetylenes I (R = 4-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, 6-methyl-3-pyridyl, 4-chloro-2,5-dimethyl-3-pyrazolyl), activated by electron-withdrawing substituents, with N<sub>2</sub>H<sub>4</sub>.cntdot.H<sub>2</sub>O afforded substituted indazoles II.  
 IT 178971-64-7P 178971-65-8P 178971-66-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (cyclocondensation of (chlorophenyl)acetylenes with hydrazine to give indazoles)  
 RN 178971-64-7 CAPLUS  
 CN 1H-Indazole, 5-nitro-3-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 178971-65-8 CAPLUS  
 CN 1H-Indazole, 3-[(6-methyl-3-pyridinyl)methyl]-5-nitro- (9CI) (CA INDEX NAME)



RN 178971-66-9 CAPLUS

CN 1H-Indazole, 3-[(4-chloro-1,3-dimethyl-1H-pyrazol-5-yl)methyl]-5-nitro-  
(9CI) (CA INDEX NAME)



L10 ANSWER 25 OF 72 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1995:490642 CAPLUS

DOCUMENT NUMBER: ~~13097-03-5~~ 163434-09-1P

TITLE: Synthesis of 1-[4-(4-phenyl-1-piperazinyl)butyl]-1,2-dihydro-3H-1,4-benzodiazepin-2-ones and -1H-indazoles and their affinity for benzodiazepine receptors

AUTHOR(S): ~~Andronati~~, S. A.; Kolodeyev, G. Ye.; Makan, S. Yu.; Sava, V. M.; Yavorsky, A. S.

CORPORATE SOURCE: Fiz.-Khim. Inst. im. A.V. Bogatskogo, Odessa, Ukraine




SOURCE: Dopov. Akad. Nauk Ukr. (1994), (8), 126-31

CODEN: DNUKEM

DOCUMENT TYPE: Journal

LANGUAGE: Russian

GI




AB Title compds. I (R = H, Cl) and II (R1 = Cl, Br, Me, R2 = H; R1 = Br, R2 = Cl) were prepd. by reaction of spiro compd. III with 1-unsubstituted benzodiazepinones and indazoles. The effect of the (phenylpiperazinyl)butyl group on the affinity to benzodiazepine receptors was examd.

IT 13097-03-5P 57614-16-1P 57639-16-4P  
163434-09-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(effect of (phenylpiperazinyl)butyl group on benzodiazepine receptor  
affinity of benzodiazepinones and indazoles)

RN 13097-03-5 CAPLUS


CN 1H-Indazole, 5-chloro-3-phenyl- (8CI, 9CI) (CA INDEX NAME)




RN 57614-16-1 CAPLUS  
CN 1H-Indazole, 5-methyl-3-phenyl- (9CI) (CA INDEX NAME)





RN 57639-16-4 CAPLUS  
CN 1H-Indazole, 5-bromo-3-phenyl- (9CI) (CA INDEX NAME)




RN 163434-09-1 CAPLUS  
CN 1H-Indazole, 5-bromo-3-(2-chlorophenyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1994:299030 CAPLUS  
 DOCUMENT NUMBER: 120:299030  
 TITLE: Total synthesis of peruvianine, a phenolic  
 7-oxoaporphine alkaloid of *Telitoxicum peruvianum*  
 AUTHOR(S): Bück, Keith T.; Edgren, Denise L.; Blake, Geoffrey W.;  
 Menachery, Mary D.  
 CORPORATE SOURCE: Fries Fries Div., Mallinckrodt, Inc., Cincinnati, OH,  
 45216, USA  
 SOURCE: Heterocycles (1993), 36(11), 2489-95  
 CODEN: HTCYAM; ISSN: 0385-5414  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 120:299030  
 GI



AB Peruvianine (I), a phenolic 7-oxoaporphine alkaloid from *Telitoxicum peruvianum*, has been synthesized via photo-Pschorr cyclization of an aminophenol precursor II.  
 IT 154458-84-1P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 RN 154458-84-1 CAPLUS  
 CN 1H-Indazol-5-ol, 3-(6,7-dimethoxy-1-isoquinolinyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1992:235509 CAPLUS

DOCUMENT NUMBER: 116:235509

TITLE: Azoles. Part 33. 5-Fluoroindazole derivatives

AUTHOR(S): Wrzećion, U.; Majewska, K.; Buege, A.; Koehler, T.;  
Rickinger, O.; Nuhn, P.

CORPORATE SOURCE: Karol Marcinkowski Med. Akad., Poznan, 60-780, Pol.

SOURCE: Pharmazie (1992), 47(1), 22-4

CODEN: PHARAT; ISSN: 0031-7144

DOCUMENT TYPE: Journal

LANGUAGE: German

AB Nitration of 5-fluoroindazole gave the 1-, 2-, and 3-nitro derivs. which were converted to amines. 5-Fluoro-3-nitroindazole caused 32.9% inhibition of phospholipase A2 at 5 .times. 10<sup>-4</sup> mol/L. and 5-chloro-3-nitroindazole gave 52.6% inhibition at the same concn. The fluoroindazoles and related chloroindazoles were inactive against 15-lipoxygenase.


IT 124673-62-7 124673-63-8

RL: RCT (Reactant)

(lipoxygenase-inhibiting activity of)


RN 124673-62-7 CAPLUS

CN 1H-Indazole, 5-chloro-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 124673-63-8 CAPLUS

CN 1H-Indazole, 5-chloro-3-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI)  
(CA INDEX NAME)




● HCl

IT 141071-17-2P 141071-18-3P 141071-20-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)


RN 141071-17-2 CAPLUS

CN 1,3'-Bi-1H-indazole, 5,5'-difluoro-3-nitro- (9CI) (CA INDEX NAME)




RN 141071-18-3 CAPLUS

CN 1H-Indazole, 5-fluoro-3-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 141071-20-7 CAPLUS

CN 1H-Indazole, 5-fluoro-3-(1-piperidinyl)- (9CI) (CA INDEX NAME)




IT 141071-14-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn., acetylation, and antiinflammatory activity of)


RN 141071-14-9 CAPLUS

CN 1H-Indazole, 5-fluoro-3-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 37 OF 72 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1990:216936 CAPLUS  
 DOCUMENT NUMBER: 112:216936  
 TITLE: Preparation of pyrazolo[1,2-a]indazolium compounds as antiasthmatics  
 INVENTOR(S): Grayshan, Roger; French, Andrew McKinnon; Al-Khammees, Hamad; De Boos, Gareth Andrew  
 PATENT ASSIGNEE(S): National Research Development Corp., UK  
 SOURCE: PCT Int. Appl., 30 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8910924	A1	19891116	WO 1989-GB517	19890512
W: JP, US				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
JP 03504242	T2	19910919	JP 1989-505608	19890512
PRIORITY APPLN. INFO.:			GB 1988-11299	19880512
			WO 1989-GB517	19890512
OTHER SOURCE(S):		MARPAT 112:216936		
GI				



AB Title compds. I [R1 = (un)substituted 6-membered N-heterocyclyl bound to a C to the indazole ring; R2 = H, HO, C1-6 alkyl, C1-6 alkoxy; R3, R4 = H, HO, halo, C1-6 alkyl, -alkoxy, O2N, cyano, H2NCO, RNHCO; R = C1-3 alkyl; R5 = H, halo; X = pharmaceutically acceptable anion; n = 1,2] useful as antiasthmatics (no data), are prepd. 3-(1-Methyl-1,2,5,6-tetrahydro-4-pyridyl)indazole (prepn. given) in DMF was added to NaH in DMF, and the mixt. added to Br(CH2)3Br in DMF to give 2,3-dihydro-9-(1,2,5,6-tetrahydro-1-methyl-4-pyridyl)pyrazole[1,2-a]indazolium bromide which was taken up in BuOH and aq. HCl to give the bromide-HCl.

IT 126971-86-6


RL: RCT (Reactant)

(reaction of, in prepn. of antiasthmatic pyrazoloindazolium compds.)


RN 126971-86-6 CAPLUS

CN 1H-Indazole, 5-chloro-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)







L10 ANSWER 42 OF 72 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1987:598159 CAPLUS  
 DOCUMENT NUMBER: 107:198159  
 TITLE: Synthesis and pharmacological activities of  
 2,3-dihydro-1H-pyrazolo[1,2-a]indazolium derivatives  
 AUTHOR(S): Fujimura, Yasuo; Shiraki, Yasuyuki; Nawata, Yoshiharu;  
 Matsunaga, Isao  
 CORPORATE SOURCE: Cent. Res. Lab., Chugai Pharm. Co., Ltd., Tokyo, 171,  
 Japan  
 SOURCE: Yakugaku Zasshi (1986), 106(11), 1002-7  
 CODEN: YKKZAJ; ISSN: 0031-6903  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Japanese  
 OTHER SOURCE(S): CASREACT 107:198159  
 GI




AB Pyrazoloindazolium halides I (R = H, 6-Me, 7-Me, 8-Me, 7-OMe, 7-OH, 7-OCH<sub>2</sub>Ph, 7-Br, 7-Cl, 7-CHO, 7-cyano, 7-CH<sub>2</sub>OH, 7-CO<sub>2</sub>H, 7-CO<sub>2</sub>Et; R<sub>1</sub> = H, Br, Me, Et, Pr, Ph; X = Cl, Br) were prepd. by N-alkylation and cyclization of indazoles II with X(CH<sub>2</sub>)<sub>3</sub>Cl. I (R = 7-Me, R<sub>1</sub> = Ph, X = Br) was more effective as a bronchodilator than isoproterenol and noradrenaline.  
 IT 65642-56-0P 83684-54-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn., alkylation, and cyclization of)  
 RN 65642-56-0 CAPLUS  
 CN 1H-Indazole-5-carboxaldehyde, 3-phenyl- (9CI) (CA INDEX NAME)




RN 83684-54-2 CAPLUS  
 CN 1H-Indazole-5-carbonitrile, 3-phenyl- (9CI) (CA INDEX NAME)







IT **57614-16-1**, 5-Methyl-3-phenylindazole  
RL: RCT (Reactant)  
(N-acetylation of)  
RN 57614-16-1 CAPLUS  
CN 1H-Indazole, 5-methyl-3-phenyl- (9CI) (CA INDEX NAME)



IT **13097-03-5**, 5-Chloro-3-phenylindazole  
RL: RCT (Reactant)  
(N-alkylation and cyclization of)  
RN 13097-03-5 CAPLUS  
CN 1H-Indazole, 5-chloro-3-phenyl- (8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 46 OF 72 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1985:523405 CAPLUS  
 DOCUMENT NUMBER: 103:123405  
 TITLE: Azoles. Part 14: behavior of 5-chloro-2-nitroindazole against aliphatic and cyclic amines  
 AUTHOR(S): W. Zechino, U.; Dudzinska-Usarewicz, J.; Majewska, K.; Stasieczko-Rydelkiewicz, I.; Stefanowicz, J.; Nieweglowska, W.  
 CORPORATE SOURCE: Acad. Med., Poznan, PL-60-780, Pol.  
 SOURCE: Pharmazie (1985), 40(2), 105-8  
 CODEN: PHARAT; ISSN: 0031-7144  
 DOCUMENT TYPE: Journal  
 LANGUAGE: German  
 OTHER SOURCE(S): CASREACT 103:123405  
 GI




AB Acetylation of 5-chloroindazole (I) by Ac<sub>2</sub>O in pyridine gave 2-acetyl-5-chloroindazole (II, R = Ac) which, on nitration in Ac<sub>2</sub>O, gave 5-chloro-1-nitroindazole. Nitration of I gave a mixt. of II (R = NO<sub>2</sub>) (III) and 5-chloro-3-nitroindazole (IV, R<sub>1</sub> = NO<sub>2</sub>) (V). Reaction of this mixt. with R<sub>2</sub>R<sub>3</sub>NH [R<sub>2</sub> = Me, R<sub>3</sub> = H; R<sub>2</sub> = R<sub>3</sub> = Me, Et; R<sub>2</sub>R<sub>3</sub> = (CH<sub>2</sub>)<sub>4</sub>, (CH<sub>2</sub>)<sub>5</sub>, O(CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>] gave a mixt. of IV (R<sub>1</sub> = R<sub>2</sub>R<sub>3</sub>N) (VI), bimol. indazole VII, and unchanged V. V was also detected in the reaction of III alone with the amines, as III isomerized to V under the reaction conditions. This isomerization also occurred photochem. and thermally.


IT 98083-58-0P 98083-61-5P 98083-64-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and acetylation of)

RN 98083-58-0 CAPLUS


CN 1H-Indazole, 5-chloro-3-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 98083-61-5 CAPLUS  
 CN 1H-Indazole, 5-chloro-3-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 98083-64-8 CAPLUS  
 CN 1H-Indazole, 5-chloro-3-(4-morpholinyl)- (9CI) (CA INDEX NAME)




IT 98083-49-9P 98083-60-4P 98083-63-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 RN 98083-49-9 CAPLUS  
 CN 1,3'-Bi-1H-indazole, 5,5'-dichloro-3-nitro- (9CI) (CA INDEX NAME)




RN 98083-60-4 CAPLUS  
 CN 1H-Indazole, 5-chloro-3-(1-pyrrolidinyl)-, monohydrochloride (9CI) (CA

INDEX NAME)



● HCl

RN 98083-63-7 CAPLUS

CN 1H-Indazole, 5-chloro-3-(1-piperidinyl)-, monohydrochloride (9CI) (CA  
INDEX NAME)

● HCl

L10 ANSWER 49 OF 72 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1984:51503 CAPLUS

DOCUMENT NUMBER: ~~100:51503~~

TITLE: The reaction of 4-alkyl-3-thiosemicarbazides with .beta.-halo ketones

AUTHOR(S): Jones, Winton D., Jr.; Kane, John M.; Sill, Arthur D.

CORPORATE SOURCE: Merrell Res. Cent., Merrell Dow Pharm. Inc.,  
Cincinnati, OH, 45215, USASOURCE: J. Heterocycl. Chem. (1983), 20(5), 1359-61  
CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 100:51503

AB The reactions of 4-alkyl-3-thiosemicarbazides with .beta.-haloalkanophenones and o-halobenzophenones gave 4,5-dihydro-N-alkyl-3-phenyl-1H-pyrazole-1-carbothioamides and 3-phenyl-1H-indazoles, resp.


IT **57614-63-8P**RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 57614-63-8 CAPLUS

CN 1H-Indazole, 5-fluoro-3-phenyl- (9CI) (CA INDEX NAME)




L10 ANSWER 51 OF 72 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 1982:472295 CAPLUS  
DOCUMENT NUMBER: 97:72295  
TITLE: Preparation of 1H-indazoles by photolysis of  
2-aminophenyl ketone O-(ethoxycarbonyl)oximes and of  
3,1,4-benzoxadiazepine-2(1H)-ones  
AUTHOR(S): Pfoertner, Kral Heinz; Foricher, Joseph  
CORPORATE SOURCE: Zent. Forschungseinheiten, F. Hoffmann-La Roche und  
Co. A.-G., Basel, CH-4002, Switz.  
SOURCE: Helv. Chim. Acta (1982), 65(3), 798-806  
CODEN: HCACAV; ISSN: 0018-019X  
DOCUMENT TYPE: Journal  
LANGUAGE: German  
GI




AB Indazoles I (R = Ph, 2-pyridyl; R1 = H, Me; R2 = Cl, Br) were obtained by photolysis of (E)- and (Z)- 2,5-R3R2C6H3CR:NOCO2Et (II, R3 = NHR1). II (R3 = NMe2) did not cyclize to I. II did not undergo E-Z isomerization. The mechanism of the photolysis reaction is discussed.

IT 13097-03-5P 82616-92-0P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 13097-03-5 CAPLUS  
CN 1H-Indazole, 5-chloro-3-phenyl- (8CI, 9CI) (CA INDEX NAME)




RN 82616-92-0 CAPLUS  
CN 1H-Indazole, 5-bromo-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)





L10 ANSWER 59 OF 72 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1978:37692 CAPLUS  
 DOCUMENT NUMBER: 88-37692  
 TITLE: Synthesis of nitroheterocycles: Part IV. Syntheses of 1-substituted 4-nitroisoquinolines, 5- and 6-nitroindazoles and 6-nitrobenzimidazoles  
 AUTHOR(S): Araya, V. P.; Fernandes, F.; Honkan, V.; Ray, D. K.; Shrivastava, V. B.  
 CORPORATE SOURCE: Ciba-Geigy Res. Cent., Bombay, India  
 SOURCE: Indian J. Chem., Sect. B (1977), 15B(7), 625-8  
 CODEN: IJSBDB  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI




AB 1-Chloro-4-nitroisoquinoline (I) was treated with oxazolidin-2-one and thiazolidin-2-one in the presence of NaH to give II (X = O, S), resp. Reaction of I with H<sub>2</sub>NCH<sub>2</sub>CH(OMe)<sub>2</sub> gives III which was cyclized to give IV. 5- And 6-nitroindazoles react with 2-halo-3- or 5-substituted-pyridines in the presence of NaH in DMF to yield 1-substituted 5- and 6-nitroindazoles (e.g., V). Similar reaction of 6-nitrobenzimidazole sodium salt with compds. contg. reactive chlorine affords 1-substituted-6-nitrobenzimidazoles (e.g., VI). The prepd. compds. possess no appreciable in vivo antibacterial, antifungal, antiamoebic or antiparasitic activity.

IT 65092-57-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)

RN 65092-57-1 CAPLUS

CN 1H-Indazole, 3-(1H-imidazol-1-yl)-5-nitro-, monohydrochloride (9CI) (CA  
 INDEX NAME)



● HCl

L10 ANSWER 65 OF 72 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1976:31053 CAPLUS  
 DOCUMENT NUMBER: 84:31053  
 TITLE: Indazole derivatives  
 INVENTOR(S): Fujimura, Yasuo; Nagano, Hiroyuki; Shindo, Minoru;  
 Kakimoto, Morio; Iwasaki, Tsuneo; Ikeda, Yugo  
 PATENT ASSIGNEE(S): Chugai Pharmaceutical Co., Ltd., Japan  
 SOURCE: Ger. Offen., 27 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2503815	A1	19750807	DE 1975-2503815	19750130
DE 2503815	C2	19860522		
JP 50106958	A2	19750822	JP 1974-12184	19740131
JP 56037984	B4	19810903		
JP 50148355	A2	19751127	JP 1974-55000	19740518
JP 59022708	B4	19840528		
JP 50154244	A2	19751212	JP 1974-61853	19740603
JP 56052904	B4	19811215		
JP 51056446	A2	19760518	JP 1974-129521	19741112
JP 60003063	B4	19850125		
JP 51063172	A2	19760601	JP 1974-135184	19741126
JP 59044313	B4	19841029		
GB 1489280	A	19771019	GB 1975-2247	19750117
FR 2259601	A1	19750829	FR 1975-2955	19750130
FR 2259601	B1	19800111		

PRIORITY APPLN. INFO.:  
 JP 1974-12184 19740131  
 JP 1974-55000 19740518  
 JP 1974-61853 19740603  
 JP 1974-129521 19741112  
 JP 1974-135184 19741126

GI For diagram(s), see printed CA Issue.

AB Indazoles I (R = R1 = H, Me, Et; R = H, R1 = Me, Bu, allyl; NRR1 = piperidino, morpholino, N-methylpiperazino, N-phenylpiperazino, 2-(4-chlorophenyl-4-methyl-1,2,3,6-tetrahydropyridino, pyrrolidino; R2 = H, Cl, Me, Br, F; n = 1-3) were prepd. by treating indazoles with Cl(CH2)nNRR1, by Mannich reaction of indazoles, or by redn. of carbamoylalkylindazoles. Thus, 3-phenylindazole was treated with Me2NCH2CH2Cl.HCl to give I (R = R1 = Me, R2 = H, n = 2), which at 100 mg/kg orally in mice had a barbiturate potentiation value of 3.0, compared with imipramine 1.3. I were also antidepressant.


IT 57614-63-8


RL: RCT (Reactant)

(Mannich reaction of, with piperidine)

RN 57614-63-8 CAPLUS

CN 1H-Indazole, 5-fluoro-3-phenyl- (9CI) (CA INDEX NAME)






IT 13097-03-5 57614-16-1 57639-16-4

RL: RCT (Reactant)  
(aminoalkylation of)


RN 13097-03-5 CAPLUS

CN 1H-Indazole, 5-chloro-3-phenyl- (8CI, 9CI) (CA INDEX NAME)




RN 57614-16-1 CAPLUS

CN 1H-Indazole, 5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 57639-16-4 CAPLUS

CN 1H-Indazole, 5-bromo-3-phenyl- (9CI) (CA INDEX NAME)




L10 ANSWER 66 OF 72 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 1975:564108 CAPLUS  
DOCUMENT NUMBER: 83:164108  
TITLE: Nucleophilic displacement of aromatic fluorine. I.  
Synthesis of benzisoxazoles  
AUTHOR(S): Walser, Armin; Flynn, Thomas; Fryer, R. Ian  
CORPORATE SOURCE: Chem. Res. Dep., Hoffmann-La Roche Inc., Nutley, N.  
J., USA  
SOURCE: J. Heterocycl. Chem. (1974), 11(6), 885-8  
CODEN: JHTCAD  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI For diagram(s), see printed CA Issue.  
AB The quinazoline 3-oxides I (R = H, Cl) convert to the  
benzisoxazoloquinazolines II by heating in Ac2O. The dihydroquinazoline-3-  
oxides III underwent aromatization under the same conditions. Hydrolysis  
of I or II gave the 3-(2-aminophenyl)benzisoxazoles IV which could be  
rearranged to the 3-(2-hydroxyphenyl)indazoles V with hydride. Possible  
mechanisms are discussed.  
IT 55076-04-5P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)  
RN 55076-04-5 CAPLUS  
CN Phenol, 2-(5-chloro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)




L10 ANSWER 70 OF 72 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1969:77962 CAPLUS  
 DOCUMENT NUMBER: 70:77962  
 TITLE: 3-Substituted indoles and indazoles  
 INVENTOR(S): Hörner, Leopold; Sues, Oskar; Simon, Ulrich  
 PATENT ASSIGNEE(S): Kalle A.-G.  
 SOURCE: Ger., 5 pp.  
 CODEN: GWXXAW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1266763		19680425	DE	19650727

GI For diagram(s), see printed CA Issue.  
 AB The title compds. (I and II) are synthetic intermediates and are prepd. by photolytic reactions of 3-diazoindoles and 3-diazoindazoles with R1H solvents. 3-Diazo-2-phenylindole (2.2 g.) in 330 ml. cyclopentene irradiated with a high-pressure Hg lamp until N evolution stops (3.5 hrs.), and the soln. worked up gave 1.15 g. 3-(2-cyclopentenyl)-2-phenylindole, m. 163-4.degree. (C6H6-cyclohexane). Similarly were obtained the following I (R1, R2, and m.p. given): 2-cyclohexenyl, Ph, 161-2.degree.; 2-cyclooctenyl, Ph, 138-40.degree.; cyclohexyl, Ph, 158-9.degree.; cyclohexyl, Me, - (picrate m. 180-1.degree.); Ph, Me, 59-60.degree.; 4-MeOC6H4, Ph, 124-5; and Ph, Ph, 189-90.degree..  
 3-Diazo-6-chloroindazole (3.6 g.) in 750 ml. C6H6 exposed 6 hrs. to direct sunlight, and the product purified by chromatog. on neutral Al2O3 in Me2CO gave 3.3 g. 3-phenyl-6-chloroindazole, m. 151-3.degree. (C6H6-cyclohexane). Similarly were prepd. the following II (R1, R2, and m.p. given): Ph8 5-Cl, 135-6.degree.; 2-pyridyl, 6-Cl, 159-60.degree.; 2(or 3)-thienyl, 6-Cl, 186-7.degree.; Ph, H, 115-16.degree.; 2(or 3),5(or 6)-ClMeC6H3(Z), H, 141-2.degree.; Ph, 4-Cl, 204-5.degree.; Z, 6-Cl, 169-70; 2,3(or 3,4)-(MeO)2C6H3, 6-Cl, 166-7.degree.; NCC6H4, 6-Cl, 288-90.degree.; MeO2CC6H4, 6-Cl, 174-5.degree.; and Ph, 5-OMe, 133-4.degree..  
 IT 13097-03-5P 13097-05-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 RN 13097-03-5 CAPLUS  
 CN 1H-Indazole, 5-chloro-3-phenyl- (8CI, 9CI) (CA INDEX NAME)



RN 13097-05-7 CAPLUS  
 CN 1H-Indazole, 5-methoxy-3-phenyl- (8CI) (CA INDEX NAME)



file  
Copy

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:545668 CAPLUS

DOCUMENT NUMBER: 135:137505

TITLE: Synthesis of disubstituted indazole compounds as cyclin dependent kinase inhibitors and methods for inhibiting cell proliferation

INVENTOR(S): Reich, Siegfried Heinz; Bleckman, Ted Michael; Kephart, Susan Elizabeth; Romines, William Henry, III; Wallace, Michael B.

PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 183 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053268	A2	20010726	WO 2001-US1477	20010118
WO 2001053268	A3	20011227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1250326	A2	20021023	EP 2001-942620	20010118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002161022	A1	20021031	US 2001-761656	20010118 <--
BR 2001007783	A	20021119	BR 2001-7783	20010118
NO 2002002117	A	20020916	NO 2002-2117	20020503
PRIORITY APPLN. INFO.:			US 2000-176484P	P 20000118
			WO 2001-US1477	W 20010118

OTHER SOURCE(S): MARPAT 135:137505

GI



AB Title compds. I [R1 = alkyl, aryl, heteroaryl, carbocycle, heterocycle, etc.; R2 = alkyl, aryl, heteroaryl, carbocycle, heterocycle, etc.] were prepd. Examples include over 90 synthetic examples and 8 bioassays. For instance, 5-amino-1H-indazole was converted to 5-chloro-3-iodo-1H-indazole by diazotization/chlorination (NaNO<sub>2</sub>, HCl, 0.degree.C/CuCl, 60.degree.C) followed by iodination (I<sub>2</sub>, NaOHaq). Protection as the N-SEM deriv. and sequential Suzuki coupling with (E)-.beta.-styreneboronic acid to the 3 position and phenylboronic acid to the 5-position yielded N-SEM deriv. I (R1 = (E)-.beta.-styrenyl; R2 = Ph). Deprotection with 3M HCl in EtOH at



reflux afforded I (R1 = (E)-.beta.-styrenyl; R2 = Ph; II). II had  $K_i = 1.7 \mu\text{M}$  for cdk4/cyclin D3 complex and  $K_i = 6.7 \mu\text{M}$  for chk1 protein kinase. Selected examples of I were also assayed for cytotoxicity (HCT 116 cell line, 69 examples). The invention is also directed to methods of treating cancer and disease states assocd. with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis.


IT 351454-76-7P 351454-82-5P 351456-19-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(synthesis of disubstituted indazole compds. as cyclin dependent kinase inhibitors and methods for inhibiting cell proliferation)


RN 351454-76-7 CAPLUS

CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 351454-82-5 CAPLUS

CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(3-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 351456-19-4 CAPLUS

CN 3-Pyridinemethanol, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl- (9CI) (CA INDEX NAME)



IT 351454-59-6P 351454-61-0P 351454-64-3P

351454-67-6P 351454-70-1P 351454-73-4P

351454-79-0P 351454-85-8P 351454-88-1P  
 351454-91-6P 351454-94-9P 351454-97-2P  
 351455-00-0P 351455-03-3P 351455-06-6P  
 351455-09-9P 351455-12-4P 351455-15-7P  
 351455-18-0P 351455-21-5P 351455-23-7P  
 351455-26-0P 351455-28-2P 351455-30-6P  
 351455-32-8P 351455-34-0P 351455-36-2P  
 351455-38-4P 351455-40-8P 351455-42-0P  
 351455-44-2P 351455-45-3P 351455-46-4P  
 351455-47-5P 351455-49-7P 351455-51-1P  
 351455-53-3P 351455-55-5P 351455-57-7P  
 351455-59-9P 351455-61-3P 351455-63-5P  
 351455-65-7P 351455-67-9P 351455-69-1P  
 351455-71-5P 351455-73-7P 351455-75-9P  
 351455-77-1P 351455-79-3P 351455-81-7P  
 351455-83-9P 351455-85-1P 351455-87-3P  
 351455-89-5P 351455-91-9P 351455-93-1P  
 351455-95-3P 351455-97-5P 351455-99-7P  
 351456-01-4P 351456-03-6P 351456-05-8P  
 351456-07-0P 351456-09-2P 351456-11-6P  
 351456-13-8P 351456-15-0P 351456-17-2P  
 351456-21-8P 351456-23-0P 351456-25-2P  
 351456-27-4P 351456-28-5P 351456-29-6P  
 351456-30-9P 351456-31-0P 351456-32-1P  
 351456-33-2P 351456-34-3P 351456-35-4P  
 351456-36-5P 351456-37-6P 351456-38-7P  
 351456-39-8P 351456-40-1P 351456-41-2P  
 351456-42-3P 351456-43-4P 351456-44-5P  
 351458-50-9P 351458-51-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of disubstituted indazole compds. as cyclin dependent kinase inhibitors and methods for inhibiting cell proliferation)

RN 351454-59-6 CAPLUS

CN 1H-Indazole, 5-phenyl-3-[(1E)-2-phenylethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 351454-61-0 CAPLUS


CN 1H-Indazole, 3,5-bis[(1E)-2-phenylethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 351454-64-3 CAPLUS

CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 351454-67-6 CAPLUS

CN Phenol, 3-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 351454-70-1 CAPLUS

CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 351454-73-4 CAPLUS

CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 351454-79-0 CAPLUS

CN Phenol, 4-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 351454-85-8 CAPLUS

CN Phenol, 3-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 351454-88-1 CAPLUS

CN 1H-Indazole, 5-(2-methylphenyl)-3-phenyl- (9CI) (CA INDEX NAME)




RN 351454-91-6 CAPLUS

CN 1H-Indazole, 3-phenyl-5-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 351454-94-9 CAPLUS

CN Phenol, 3-methyl-4-(3-phenyl-1H-indazol-5-yl)- (9CI) (CA INDEX NAME)




RN 351454-97-2 CAPLUS  
 CN 1H-Indazole, 3-phenyl-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 351455-00-0 CAPLUS  
 CN Phenol, 2-methyl-3-[3-[(1E)-2-phenylethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 351455-03-3 CAPLUS  
 CN Isoquinoline, 4-[3-[(1E)-2-phenylethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 351455-06-6 CAPLUS  
 CN Quinoline, 4-[3-[(1E)-2-phenylethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 351455-09-9 CAPLUS

CN 1H-Indazole, 5-(4-pyridinyl)-3-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)




RN 351455-12-4 CAPLUS

CN Isoquinoline, 4-[3-(4-chloro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]- (9CI)  
(CA INDEX NAME)




RN 351455-15-7 CAPLUS

CN Isoquinoline, 4-[3-[5-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 351455-18-0 CAPLUS


CN 1H-Benzimidazol-4-ol, 2-[5-(3-hydroxy-2-methylphenyl)-1H-indazol-3-yl]-  
(9CI) (CA INDEX NAME)



RN 351455-21-5 CAPLUS


CN Benzenepropanol, 2-hydroxy-3-methyl-4-[3-[(1E)-2-phenylethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 351455-23-7 CAPLUS


CN 1H-Benzimidazole-4-methanol, 2-[5-(3-hydroxy-2-methylphenyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



RN 351455-26-0 CAPLUS


CN Isoquinoline, 7-[3-[(1E)-2-phenylethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 351455-28-2 CAPLUS

CN Isoquinoline, 4-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 351455-30-6 CAPLUS


CN Benzenepropanol, 4-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-2-hydroxy-3-methyl- (9CI) (CA INDEX NAME)



RN 351455-32-8 CAPLUS

CN 4-Piperidinol, 1-[3-[(1E)-2-phenylethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 351455-34-0 CAPLUS


CN 3-Piperidinol, 1-[3-[(1E)-2-phenylethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 351455-36-2 CAPLUS

CN 1H-Benzimidazole-4-methanol, 2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)




RN 351455-38-4 CAPLUS

CN 1H-Benzimidazole-4-ethanol, 2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)




RN 351455-40-8 CAPLUS


CN 1H-Benzimidazole-4-methanamine, 2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 351455-42-0 CAPLUS  
 CN 1H-Benzimidazole-4-methanamine, 2-[5-(4-isoquinoliny)-1H-indazol-3-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 351455-44-2 CAPLUS  
 CN Isoquinoline, 4-[3-[4-(1-pyrrolidinylmethyl)-1H-benzimidazol-2-yl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 351455-45-3 CAPLUS  
 CN Isoquinoline, 4-[3-[4-[2-(1-pyrrolidinyl)ethyl]-1H-benzimidazol-2-yl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 351455-46-4 CAPLUS

CN 1-Propanol, 3-[[[2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]-1H-benzimidazol-4-yl]methyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 351455-47-5 CAPLUS

CN 1H-Benzimidazole-4-methanamine, N,N-diethyl-2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)




RN 351455-49-7 CAPLUS

CN 1H-Benzimidazole-4-methanamine, N-ethyl-2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)




RN 351455-51-1 CAPLUS

CN 1H-Benzimidazole-4-methanamine, 2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 351455-53-3 CAPLUS

CN 1H-Benzimidazole-4-methanamine, N-(1,1-dimethylethyl)-2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



RN 351455-55-5 CAPLUS


CN Isoquinoline, 4-[3-[4-(1H-imidazol-1-ylmethyl)-1H-benzimidazol-2-yl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 351455-57-7 CAPLUS

CN 1H-Indazole, 5-(3-methyl-4-pyridinyl)-3-[(1E)-2-phenylethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 351455-59-9 CAPLUS

CN 1H-Indazole, 5-(4-chloro-3-pyridinyl)-3-[(1E)-2-phenylethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 351455-61-3 CAPLUS

CN 1H-Indazole, 5-(4-methyl-3-pyridinyl)-3-[(1E)-2-phenylethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 351455-63-5 CAPLUS

CN Isoquinoline, 5-fluoro-4-[3-[(1E)-2-phenylethenyl]-1H-indazol-5-yl]- (9CI)  
(CA INDEX NAME)


Double bond geometry as shown.



RN 351455-65-7 CAPLUS

CN 8-Isoquinolinamine, 4-[3-[(1E)-2-phenylethenyl]-1H-indazol-5-yl]- (9CI)  
(CA INDEX NAME)


Double bond geometry as shown.



RN 351455-67-9 CAPLUS


CN 1H-Indazole, 5-(4-chloro-5-ethyl-3-pyridinyl)-3-[(1E)-2-phenylethenyl]-  
(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 351455-69-1 CAPLUS

CN Phenol, 3-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 351455-71-5 CAPLUS

CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(1H-indol-4-yl)- (9CI) (CA INDEX NAME)




RN 351455-73-7 CAPLUS


CN Phenol, 3-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-2,4-difluoro- (9CI) (CA INDEX NAME)




RN 351455-75-9 CAPLUS  
 CN Phenol, 4-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-3,5-difluoro- (9CI)  
 (CA INDEX NAME)




RN 351455-77-1 CAPLUS  
 CN Phenol, 2-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-3,5-difluoro- (9CI)  
 (CA INDEX NAME)




RN 351455-79-3 CAPLUS  
 CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(4-chloro-3-pyridinyl)- (9CI) (CA  
 INDEX NAME)



RN 351455-81-7 CAPLUS  
 CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(4-methyl[3,4'-bipyridin]-5-yl)- (9CI) (CA INDEX NAME)









RN 351455-83-9 CAPLUS

CN 1,7-Naphthyridine, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 351455-85-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-8-isoquinolinyl]- (9CI) (CA INDEX NAME)




RN 351455-87-3 CAPLUS

CN Acetamide, N-[4-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-8-isoquinolinyl]- (9CI) (CA INDEX NAME)




RN 351455-89-5 CAPLUS

CN 8-Isoquinolinamine, 4-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 351455-91-9 CAPLUS


CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(4-methyl[3,3'-bipyridin]-5-yl)- (9CI) (CA INDEX NAME)



RN 351455-93-1 CAPLUS


CN 2-Propen-1-ol, 3-[5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-3-pyridinyl]-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 351455-95-3 CAPLUS

CN 3-Pyridinepropanol, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-(9CI) (CA INDEX NAME)




RN 351455-97-5 CAPLUS

CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(4-ethyl[3,4'-bipyridin]-5-yl)-(9CI) (CA INDEX NAME)




RN 351455-99-7 CAPLUS

CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(4'-methyl[2,3'-bipyridin]-5'-yl)-  
(9CI) (CA INDEX NAME)




RN 351456-01-4 CAPLUS

CN 1,7-Naphthyridine, 1-acetyl-5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-  
1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 351456-03-6 CAPLUS

CN 3-Pyridinecarboxamide, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 351456-05-8 CAPLUS

CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-[5-(1H-imidazol-4-yl)-4-methyl-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 351456-07-0 CAPLUS

CN Isoquinoline, 4-[3-(4,5,6,7-tetrahydro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 351456-09-2 CAPLUS

CN Isoquinoline, 4-[3-(4-methyl-5-phenyl-1H-imidazol-2-yl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 351456-11-6 CAPLUS

CN 1H-Benzimidazole-4-methanamine, N,N-dimethyl-2-[5-(4-methyl[3,4'-bipyridin]-5-yl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)




RN 351456-13-8 CAPLUS

CN Benzenemethanol, 3-[5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 351456-15-0 CAPLUS

CN Methanesulfonamide, N-[2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 351456-17-2 CAPLUS

CN Methanesulfonamide, N-[2-[5-(4-methyl[3,4'-bipyridin]-5-yl)-1H-indazol-3-yl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 351456-21-8 CAPLUS

CN 3-Pyridinemethanamine, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N,N,4-trimethyl- (9CI) (CA INDEX NAME)




RN 351456-23-0 CAPLUS

CN 3-Pyridinemethanamine, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N-ethyl-4-methyl- (9CI) (CA INDEX NAME)




RN 351456-25-2 CAPLUS

CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(4,5-dimethyl-3-pyridinyl)- (9CI)  
(CA INDEX NAME)




RN 351456-27-4 CAPLUS

CN Quinoline, 3-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl- (9CI)  
(CA INDEX NAME)



RN 351456-28-5 CAPLUS

CN 3-Pyridinol, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl- (9CI)  
(CA INDEX NAME)




RN 351456-29-6 CAPLUS

CN 3-Pyridinemethanamine, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-




methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 351456-30-9 CAPLUS

CN 1H-Pyrrol-1-amine, N-[[5-(4-isoquinolinyl)-1H-indazol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 351456-31-0 CAPLUS

CN 1H-Benzimidazole-4-carboxamide, 2-[5-[5-[(ethylamino)methyl]-4-methyl-3-pyridinyl]-1H-indazol-3-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 351456-32-1 CAPLUS

CN 3-Pyridinemethanamine, N-ethyl-4-methyl-5-[3-[4-(methylthio)-1H-benzimidazol-2-yl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)




RN 351456-33-2 CAPLUS

CN Acetamide, N-[2-[5-[5-[(ethylamino)methyl]-4-methyl-3-pyridinyl]-1H-indazol-3-yl]-1H-benzimidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 351456-34-3 CAPLUS

CN 1H-Indazole, 5-(2,6-difluorophenyl)-3-phenyl- (9CI) (CA INDEX NAME)



RN 351456-35-4 CAPLUS


CN 1H-Indazol-5-amine, 3-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



*Claim 12*


RN 351456-36-5 CAPLUS

CN 1H-Indazol-5-amine, N-(phenylmethyl)-3-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)




*claim 12*


RN 351456-37-6 CAPLUS  
CN 1H-Indazole, 5-(3-methoxyphenyl)-3-phenyl- (9CI) (CA INDEX NAME)




RN 351456-38-7 CAPLUS  
CN 3-Pyridinemethanamine, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N-(1,1-dimethylethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 351456-39-8 CAPLUS  
CN 3-Pyridinemethanamine, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 351456-40-1 CAPLUS  
CN Ethanol, 2-[[[5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-3-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 351456-41-2 CAPLUS

CN 1H-Benzimidazole-4-methanamine, 2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]-N,.alpha.-dimethyl- (9CI) (CA INDEX NAME)




RN 351456-42-3 CAPLUS

CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-[4-methyl-5-(4-morpholinylmethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 351456-43-4 CAPLUS

CN 3-Pyridinemethanamine, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N-cyclopentyl-4-methyl- (9CI) (CA INDEX NAME)




RN 351456-44-5 CAPLUS

CN 3-Pyridinemethanamine, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 351458-50-9 CAPLUS

CN 1H-Indazole, 3-phenyl-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 351458-51-0 CAPLUS

CN 1H-Indazole, 5-nitro-3-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



IT 293758-67-5P 351456-92-3P 351457-10-8P


351457-27-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of disubstituted indazole compds. as cyclin dependent kinase inhibitors and methods for inhibiting cell proliferation)

RN 293758-67-5 CAPLUS


CN 1H-Indazole, 5-nitro-3-phenyl- (9CI) (CA INDEX NAME)



RN 351456-92-3 CAPLUS


CN 1H-Indazole, 5-(3-methoxy-2-methylphenyl)-3-[(1E)-2-phenylethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 351457-10-8 CAPLUS

CN 1H-Indazole, 5-(4-pyridinyl)-3-[1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrol-2-yl]- (9CI) (CA INDEX NAME)



RN 351457-27-7 CAPLUS

CN 1H-Benzimidazol-4-ol, 2-[5-(3-methoxy-2-methylphenyl)-1H-indazol-3-yl]-  
(9CI) (CA INDEX NAME)